Functional Genomics for Cell-Therapy Matching: Optimizing Precision in Regenerative Medicine

Abstract

Functional genomics is revolutionizing cell-therapy matching by enabling molecularly precise selection and optimization of donor and recipient cells. Through high-throughput sequencing, transcriptomic profiling, and integration of multi-omics data, clinicians can now individualize cell therapies, improving efficacy and safety. This review explores the role of functional genomics in cell-therapy matching, summarizing current evidence, underlying mechanisms, risk stratification, diagnostic advancements, management strategies, recent innovations, and guideline recommendations, with a focus on clinical application for physicians and healthcare professionals.

Introduction

The advent of cell-based therapies including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptor (CAR) T-cell therapies, and mesenchymal stromal cell (MSC) infusions has transformed the landscape of regenerative medicine. However, their widespread success is hindered by barriers in matching, immunogenicity, and variable engraftment. Functional genomics, which investigates gene function and regulation at a systems level, offers a powerful approach to overcome these barriers. By elucidating the molecular phenotypes of both donor and recipient cells, functional genomics facilitates the selection of optimal cell sources and prediction of therapeutic outcomes. This review provides an in-depth analysis of the latest developments in functional genomics for cell-therapy matching, tailored for clinicians seeking evidence-based strategies to enhance patient outcomes.

Epidemiology / Disease Burden

Cell therapies are increasingly employed for a broad range of diseases, including hematological malignancies, congenital immunodeficiencies, autoimmune disorders, and degenerative conditions. According to recent global estimates, over 50,000 HSCTs and several thousand CAR-T infusions are performed annually. Nonetheless, treatment failure, graft-versus-host disease (GVHD), and relapse remain significant clinical challenges, with mismatch complications contributing to morbidity and mortality. The rising burden underscores the necessity for advanced matching techniques that can maximize therapeutic benefit while minimizing adverse effects. Functional genomics by refining selection criteria has the potential to reduce these burdens at a population level.

Pathophysiology

The pathophysiological basis of successful cell therapy hinges on molecular compatibility between donor and recipient. Traditional human leukocyte antigen (HLA) matching, while critical, fails to capture the complexity of gene expression, epigenetic modifications, and regulatory networks influencing immunogenicity, engraftment, and therapeutic activity. Functional genomics encompasses transcriptomics, proteomics, and single-cell sequencing to characterize cellular phenotypes, immune repertoires, and signaling pathways at unparalleled resolution. This approach can identify minor histocompatibility antigens, neoantigen profiles, and gene expression signatures predictive of immune responses and cellular function, informing the optimal pairing of donor and recipient.

Risk Factors

Suboptimal cell-therapy outcomes are influenced by a spectrum of genomic and clinical risk factors. These include HLA mismatches, minor antigen discordance, donor-specific antibodies, underlying comorbidities, and recipient immune status. Functional genomic profiling can stratify risk by identifying gene variants associated with GVHD, relapse, or poor engraftment. For example, single-nucleotide polymorphisms (SNPs) in cytokine genes or immune checkpoint regulators may predispose to inflammatory complications. Furthermore, transcriptomic analysis of cell products can reveal exhaustion markers or pro-inflammatory signatures, guiding risk mitigation strategies prior to therapy.

Clinical Features

Clinical manifestations of mismatch or suboptimal cell-therapy pairing can range from acute rejection and GVHD to delayed or failed engraftment, infection, and relapse. Functional genomics enables pre-therapeutic characterization of both donor and recipient, allowing clinicians to anticipate and monitor for such adverse features. For instance, patients with high-risk genomic profiles may require intensified surveillance or adjunctive immunosuppression, while those matched at a molecular level may experience fewer complications and improved quality of life.

Diagnosis

Genomic-based diagnostics are rapidly transitioning from research to clinical practice. Advances in next-generation sequencing (NGS), single-cell RNA sequencing, and CRISPR-based functional screening have enabled comprehensive profiling of both donor cell products and recipient immune landscapes. Diagnostic algorithms now integrate HLA typing with transcriptomic and proteomic data, improving prediction of engraftment potential, immune compatibility, and long-term outcomes. Liquid biopsy and cell-free DNA analysis further enhance post-infusion monitoring, detecting early signs of relapse or immune activation with high sensitivity.

Treatment & Management

Functional genomics informs all stages of cell-therapy management from donor selection and product manufacturing to post-infusion monitoring. Clinicians can leverage genomic data to select donors with optimal immune profiles, screen for deleterious variants, and tailor conditioning regimens. Post-therapy, functional profiling supports real-time tracking of therapeutic cells, identification of clonal evolution, and early detection of complications. Personalized immunosuppression and targeted interventions are increasingly guided by dynamic genomic and transcriptomic data, optimizing outcomes for high-risk patients.

Recent Advances / Emerging Therapies

Recent breakthroughs in multi-omics integration, machine learning, and single-cell analytics have propelled functional genomics to the forefront of cell-therapy matching. Notably, algorithms that combine HLA typing with gene expression and T-cell receptor repertoire analysis are improving the precision of donor-recipient matching. Novel approaches, such as CRISPR-based editing to eliminate immunogenic epitopes and the use of induced pluripotent stem cell (iPSC) lines with engineered immune invisibility, are under active investigation. These advances promise to expand the eligible pool of donors, reduce rejection, and improve durability of cell therapies.

Guideline Recommendations

Leading clinical guidelines now recognize the value of incorporating functional genomic data alongside traditional HLA matching for cell therapies. The European Society for Blood and Marrow Transplantation (EBMT) and American Society for Transplantation and Cellular Therapy (ASTCT) recommend integrating NGS-based genotyping and transcriptomic analysis where feasible, particularly in high-risk or heavily pretreated patients. Ongoing clinical trials are expected to further refine these recommendations, establishing functional genomics as a standard component of cell-therapy protocols.

Conclusion

Functional genomics is fundamentally reshaping the paradigm of cell-therapy matching, enabling molecularly informed, patient-specific interventions and improving clinical outcomes. As high-throughput technologies become more accessible, the integration of multi-omics data into everyday clinical practice will likely become standard of care. Continued research, robust clinical validation, and interdisciplinary collaboration will be essential to fully realize the potential of functional genomics in optimizing regenerative medicine for diverse patient populations.